Themis Medicare Ltd. Navigates Headwinds with Strategic Focus and Profitability Turnaround in Q3 FY26

Feb 15, 2026•3 min read

Themis Medicare Ltd

THEMISMED

Ask AI

Themis Medicare Limited, a prominent player in the Indian pharmaceutical sector, recently unveiled its financial results for the third quarter and nine months ending FY26. Despite facing some significant top-line pressures and disruptions in a key business segment, the company has demonstrated remarkable resilience, reporting a positive turnaround in profitability for Q3 FY26. This period highlights the management's strategic agility in optimizing operations and focusing on high-growth areas amidst challenging market conditions.

For Q3 FY26, Themis Medicare reported a consolidated revenue of ₹90.13 crore. While this represents a slight year-on-year decrease of 3.9% from ₹93.81 crore in Q3 FY25, the profitability metrics tell a more encouraging story. The company's EBITDA grew by 14.9% year-on-year to ₹9.80 crore, up from ₹8.53 crore in the corresponding quarter last year. This improvement was largely driven by effective cost rationalization measures, which boosted the EBITDA margin by 178 basis points to 10.87%. Furthermore, Profit After Tax (PAT) saw an extraordinary surge, increasing by 1843.7% to ₹10.09 crore in Q3 FY26 from a mere ₹0.52 crore in Q3 FY25, with PAT margin expanding to 11.20%.

However, the nine-month period (9M FY26) presented a more challenging picture, with net revenue declining by 20.4% to ₹265.71 crore from ₹333.81 crore in 9M FY25. This was accompanied by negative EBITDA of ₹(3.37) crore and a negative PAT of ₹(7.74) crore, reflecting the cumulative impact of earlier disruptions and sluggishness in certain segments.

Financial Metric (₹ Crore)	Q3 FY26	Q3 FY25	Y-o-Y (%)	9M FY26	9M FY25	Y-o-Y (%)
Net Revenue	90.13	93.81	(3.9%)	265.71	333.81	(20.4%)
EBITDA	9.80	8.53	14.9%	(3.37)	54.83	(106.1%)
PAT	10.09	0.52	1843.7%	(7.74)	39.50	(119.6%)
EBITDA Margin (%)	10.87%	9.09%	178 Bps	(1.27%)	16.43%	-
PAT Margin (%)	11.20%	0.55%	1065 Bps	(2.91%)	11.83%	-

Strategic Business Performance and Future Outlook

Dr. Sachin Patel, Managing Director & CEO, acknowledged the

Frequently Asked Questions

In Q3 FY26, Themis Medicare reported a positive turnaround in profitability. EBITDA grew 15% year-on-year to ₹9.8 crore, and PAT increased significantly by 1843.7% to ₹10.09 crore. The EBITDA margin improved by 178 bps to 10.9%.

The API business more than doubled year-on-year in Q3 FY26. Both the Trade and Hospital businesses also showed year-on-year improvement, despite overall top-line pressure and sluggishness in the formulations business.

The company aims to become a leader in the Hospital Business in India by expanding chain hospital contracts and increasing its presence in nursing homes. The focus is on high-margin products and leveraging its expertise in complex injectables.

Themis Medicare has a two-phase international expansion strategy. Phase I involves expanding into new RoW Markets (CIS, Latin America, GCC) within 0-3 years. Phase II targets entry into regulated markets (EU, USA) within 3-5 years.

The company is implementing cost rationalization measures, which have already improved EBITDA margins. It also maintains a strong R&D pipeline, allocating 3% of its revenue to R&D, with efforts directed towards creating differentiated products in key therapeutic areas.

For the nine-month period (9M FY26), Themis Medicare's net revenue decreased by 20.4% to ₹265.71 crore. The company reported a negative EBITDA of ₹(3.37) crore and a negative PAT of ₹(7.74) crore for this period.

Did your stocks survive the war?

See what broke. See what stood.

Live Q4 Earnings Tracker

View all

Themis Medicare Q 3 Fy 26 Update

Themis Medicare Ltd. Navigates Headwinds with Strategic Focus and Profitability Turnaround in Q3 FY26